QIAGEN Partners with Verogen to Offer Broadest Human Identification Portfolio, Including Next Generation Sequencing Solutions

GERMANTOWN, Maryland & HILDEN, Germany – (COMMERCIAL THREAD) – QIAGEN NV (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced a marketing partnership with San Diego-based human identification specialist Verogen, which will provide customers of both companies with quality tools superior and comprehensive support for Human Identification (HID) workflows in their labs.

Agreement Enables QIAGEN to Offer Verogen’s Preeminent HID Sequencing and Analysis Solutions That Run on MiSeq FGx® Sequencers from Illumina, decisively extending QIAGEN’s forensic leadership that already covers sample collection and preparation, genetic test analysis and workflow automation. The agreement grants QIAGEN the rights to distribute the Verogen portfolio worldwide, including kits based on the proprietary Verogen ForenSeq.® test, the Verogen MiSeq FGx® Sequencing system and universal analysis software – and covers an expansion of the partnership through future tests based on ForenSeq.

Verogen and QIAGEN will also cooperate to commercialize a menu of forensic validated workflows for Next Generation Sequencing (NGS) that combines Verogen’s library prep products with products, automation solutions and l QIAGEN’s QIAseq expertise. QIAGEN will market Verogen products globally alongside its portfolio of forensic instruments, kits and services. Financial details of the deal are not being disclosed.

“This combination brings together Verogen’s innovative NGS workflows with QIAGEN’s leading portfolio of Sample to Insight solutions, creating the most comprehensive product offering for forensic applications,” said Thierry Bernard, CEO of QIAGEN . “The partnership will drive the adoption of NGS in human identification, as it will allow our clients to gain even better information from their sample records. This will ultimately strengthen justice systems around the world. ”

“Our mission is to equip the human identification community with innovative tools capable of providing identification, not just a DNA profile,” said Brett Williams, CEO of Verogen. “This partnership with QIAGEN will make it easier for laboratories to provide more impactful responses. By combining Verogen’s industry-leading NGS product portfolio with QIAGEN’s benchmark extraction, analysis and automation solutions, we will accelerate the adoption and use of NGS in forensics.

NGS is used in many areas of biotechnology, from cancer research to testing for rare diseases. In forensics, this opens up whole new opportunities for dealing with criminal cases, missing persons and the identification of disaster victims. While traditional STR profiling requires a suspect or a database to compare with a crime sample, NGS provides additional intelligence options such as estimating externally visible features like hair or eye color, thus elevating DNA testing from passive forensic support to proactive technical investigation.

Experts expect the market for forensic NGS to grow at double-digit rates every year due to its promising applications.

This collaboration of market leaders addresses significant barriers in areas such as workflow integration, automation and vendor support that have slowed the adoption of NGS in forensics. The partnership strengthens the workflow solutions offered by QIAGEN and Verogen by offering forensic clients a new level of end-to-end support across the world, from sample collection to interpretation and analysis Datas.

QIAGEN is a global leader in HID and forensic testing. It offers a full line of forensic grade chemicals and high quality instruments, such as the new EZ2 Connect Fx, that meet the challenges of crime scene investigations and more. Covering every step, from sample to analysis, QIAGEN has shaped the development of forensic standards, supporting criminal justice and the identification of missing persons. QIAGEN’s premium forensic products and services help customers unlock vital molecular information to make improvements in life possible.

To learn more about QIAGEN’s Human Identification Wallet, click here: https://www.qiagen.com/us/applications/human-identity-and-forensics/

About Verogen

Verogen is a dedicated developer of DNA-based biometric human identification products for the analysis of forensic genomic samples. Working closely with the forensic community, Verogen places exceptional value on flexible and scalable solutions that deliver reliable results. To learn more, visit www.verogen.com


QIAGEN NV, a Netherlands-based holding company, is the world’s leading provider of Sample to Insight solutions that enable customers to gain valuable molecular information from samples containing the building blocks of life. Our sampling technologies isolate and process DNA, RNA and proteins from blood, tissues and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to provide relevant and actionable information. Automation solutions link them together in transparent and cost-effective workflows. QIAGEN provides solutions to more than 500,000 customers worldwide in the fields of molecular diagnostics (human health) and life sciences (universities, pharmaceutical R&D and industrial applications, mainly forensics). As of March 31, 2021, QIAGEN employed approximately 5,700 people at more than 35 locations around the world. Further information is available at http://www.qiagen.com

Forward-looking statement

Certain statements in this press release may be deemed to be forward-looking statements within the meaning of Section 27A of the US Securities Act of 1933, as amended, and Section 21E of the US Securities Exchange Act of 1934, as amended. . To the extent that any of the statements contained herein regarding QIAGEN’s products, including products used in the COVID-19 pandemic response, launch and development schedule, marketing approvals, and / or regulatory, financial and operational outlook, growth and expansion, collaborative markets, strategy or operating results, including, without limitation, its expected adjusted net sales and adjusted earnings results diluted, are forward-looking, these statements are based on current expectations and assumptions which involve a number of uncertainties and risks. These uncertainties and risks include, but are not limited to, risks associated with managing growth and international operations (including the effects of currency fluctuations, regulatory processes and reliance on logistics), variability in operating results and allocations between customer categories; commercial development of markets for our products to academic, pharmaceutical, applied testing and molecular diagnostics customers; changing relationships with customers, suppliers and strategic partners; competetion; rapid or unexpected technological changes; fluctuations in demand for QIAGEN’s products (including fluctuations due to general economic conditions, level and timing of customer financing, budgets and other factors); our ability to obtain regulatory approval for our products; difficulties in successfully adapting QIAGEN’s products to integrated solutions and producing such products; QIAGEN’s ability to identify and develop new products and to differentiate and protect our products from competitive products; market acceptance of new QIAGEN products and integration of acquired technologies and businesses; government actions, global or regional economic developments, weather or transport delays, natural disasters, political or public health crises, including the extent and duration of the COVID-19 pandemic and its impact on demand for our products and other aspects of our business, or other force majeure events; as well as the possibility that the expected benefits of recent or ongoing acquisitions will not materialize as expected; and other factors discussed under the heading “Risk Factors” in Item 3 of our most recent Annual Report on Form 20-F. For more information, please refer to the discussions in reports that QIAGEN has filed with or provided to the United States Securities and Exchange Commission.


Category: Company

Comments are closed.